LeMaitre Vascular Inc (LMAT) company profile
Close on Nov 17, 2026Market cap $1.74BP/E 26.7Yield 1.05%
About LeMaitre Vascular
Surgical & Medical Instruments & Apparatus, SIC 3841
LeMaitre Vascular, Inc. is a medical device company that develops, manufactures, and markets vascular devices and provides human tissue cryopreservation services. Its products are primarily designed for use in open surgical procedures, including open vascular and open cardiac surgeries, to treat peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company's portfolio features six product categories encompassing twenty-four distinct product types, such as valvulotomes, balloon catheters, carotid shunts, vascular grafts, patches, and vessel closure systems. LeMaitre Vascular primarily serves vascular surgeons, while also providing products and tissue processing services to cardiac surgeons, general surgeons, and neurosurgeons.
The company operates globally, conducting direct-to-hospital sales and marketing through regional headquarters and offices across North America, Europe, and Asia Pacific. Its corporate headquarters is located in Burlington, Massachusetts, where it also maintains primary manufacturing operations. Additional corporate and sales presences include a European headquarters in Sulzbach, Germany, an Asia Pacific headquarters in Singapore, and multiple regional sales offices in countries such as Canada, Italy, Spain, England, Ireland, France, Switzerland, Japan, China, Australia, Korea, and Thailand. Outside these direct territories, the company distributes products via independent distributors.
Summary of the business section of LeMaitre Vascular's latest annual report, written by StockData.
Company profile
Company
- Legal name
- LeMaitre Vascular Inc
- Founded
- 1983
- Headquarters
- Burlington, MA
- Address
- 63 Second Avenue 01803
- Phone
- (781) 221-2266
- Website
- lemaitre.com
- Employees
- 655, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Fiscal year ends
- December 31
- Auditor
- GRANT THORNTON LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- LMAT
- Exchange
- Nasdaq
- IPO date
- Oct 19, 2006
- Shares outstanding
- 23M, Aug 2, 2026
- Public float
- $1.70B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1158895
- CUSIP
- 525558201
- ISIN
- US5255582018
- FIGI
- BBG000LY1HS2
- Share class FIGI
- BBG001SK6CX3
- LEI
- 549300FZUBUB7MHY8R17
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| George W. LeMaitre | Chairman and CEO, Director | 1,463,419 |
| David B. Roberts | President and Director | 14,667 |
| Dorian Paul LeBlanc | Chief Financial Officer | 2,302 |
| Trent G. Kamke | Senior V. P., Operations | 3,749 |
| John James O'Connor | Director | 62,826 |
| John A. Roush | Director | 7,567 |
| Lawrence J. Jasinski | Director | 7,792 |
| Martha Shadan | Director | 2,961 |
| Joseph P. Pellegrino JR | Director | 15,021 |
| Bridget A. Ross | Director | 8,986 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $3.78B | $4.21B | $911.59M | $210000 | $116000 |
| FY2024 | $3.24B | $8.32B | $1.11B | $236000 | $109000 |
| FY2023 | $2.22B | $4.43B | $956.47M | $144000 | $100000 |
| FY2022 | $1.94B | $2.43B | $876.24M | $116000 | $97000 |
| FY2021 | $1.98B | $5.34B | $905.07M | $125000 | $121000 |
| FY2020 | $1.39M | $3.11M | $598.05K | $114 | $124 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| George W. LeMaitre Chairman and Chief Executive Officer | $806.35K | – | $1.05M | $1.05M | $680.02K | $194.63K | $3.78M | +17% |
| Joseph P. Pellegrino, Jr. Former Chief Financial Officer | $88.82K | $2.83K | – | – | – | $244.24K | $335.89K | -74% |
| Dorian P. LeBlanc Chief Financial Officer | $445.48K | $8.00K | $196.88K | $196.88K | $220.06K | $10.50K | $1.08M | – |
| David B. Roberts President | $452.71K | $40.50K | $283.50K | $283.50K | $202.64K | $10.50K | $1.27M | +11% |
| Trent G. Kamke Senior Vice President, Operations | $383.82K | $12.00K | $196.88K | $196.88K | $159.25K | $10.50K | $859.35K | 0% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Oct 19, 2006
- Offer price
- $7.00
- Securities offered
- 5,500,000
- Gross proceeds
- $38.50M
- Exchange
- Nasdaq
- First trading day
- Oct 19, 2006
- First-day close
- $6.20-11.4%
- Lock-up ends (est.)
- Apr 17, 2007
“Per Share Total Initial public offering price $ 7.00 $ 38,500,000 Underwriting discount $ 0.49 $ 2,695,000 Proceeds, before expenses, to LeMaitre Vascular $ 6.51 $ 35,805,000 To the extent that the underwriters sell more than 5,500,000 shares of common stock, the underwriters have the option to purchase up to an ad”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“We had 655 employees, including 646 full-time employees, as of December 31, 2025.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 17, 2019 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Sep 26, 2018 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Nov 10, 2016 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Mar 27, 2015 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Aug 8, 2008 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 31, 2007 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 24, 2007 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 19, 2006 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 17, 2006 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?